Noteworthy Activity Observed With Frontline Avelumab in Cisplatin-Ineligible, PD-L1+ Advanced UC, Despite Missing 1-Year OS End Point
[ad_1] In the phase 2 ARIES clinical trial (NCT03891238), treatment with avelumab (Bavencio) did not demonstrate an improvement in overall survival (OS) at 1 year as frontline treatment in patients […]




















